Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mercaptopurine efficacy based on NUDT15 polymorphism after allogeneic stem cell transplantation relapse
jRCT1051200006Completed
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mercaptopurine in Acute Leukaemia and myelodysplastic syndrome-transformed acute myeloid leukemia (AML-MRC). Primary endpoint: Anti-leukemia effect of mercaptopurine. Started Apr 2020; status: completed.
02
Drugs
mercaptopurine
03
Conditions
Acute Leukaemiamyelodysplastic syndrome-transformed acute myeloid leukemia (AML-MRC)
Beyond the preview
Go deeper on jRCT1051200006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051200006.